Premium
The outliers become a stampede as immunometabolism reaches a tipping point
Author(s) -
Nikolajczyk Barbara S.,
JagannathanBogdan Madhumita,
Denis Gerald V.
Publication year - 2012
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/j.1600-065x.2012.01142.x
Subject(s) - immune system , immunology , inflammation , insulin resistance , type 2 diabetes , chemokine , biology , adipose tissue , obesity , diabetes mellitus , medicine , endocrinology
Summary: Obesity and Type 2 diabetes mellitus (T2D) are characterized by pro‐inflammatory alterations in the immune system including shifts in leukocyte subset differentiation and in cytokine/chemokine balance. The chronic, low‐grade inflammation resulting largely from changes in T‐cell, B‐cell, and myeloid compartments promotes and/or exacerbates insulin resistance (IR) that, together with pancreatic islet failure, defines T2D. Animal model studies show that interruption of immune cell‐mediated inflammation by any one of several methods almost invariably results in the prevention or delay of obesity and/or IR. However, anti‐inflammatory therapies have had a modest impact on established T2D in clinical trials. These seemingly contradictory results indicate that a more comprehensive understanding of human IR/T2D‐associated immune cell function is needed to leverage animal studies into clinical treatments. Important outstanding analyses include identifying potential immunological checkpoints in disease etiology, detailing immune cell/adipose tissue cross‐talk, and defining strengths/weaknesses of model organism studies to determine whether we can harness the promising new field of immunometabolism to curb the global obesity and T2D epidemics.